Raily Aesthetic Medicine International Holdings Limited provided earnings guidance for the period ending December 31, 2021. For the period, the company expects the Group to record a revenue of approximately RMB 188 million for the year ended 31 December 2021 (2020: revenue of approximately RMB 165 million); and the Board expects the Group to record a loss attributable to the shareholders of the parent
of approximately RMB 18 million for the year ended 31 December 2021 (2020: profit of
approximately RMB 4 million).